Here, we performed this multicenter retrospective study to investigate the impact of BrMs on the efficacy of ICI based treatments in NSCLC, and the outcome differences between PD-1/PD-L1 inhibitor-based monotherapy and combination therapies in patients with NSCLC and BrMs. Here, PDCD1 is linked to non-small cell lung carcinoma.